A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the
prevention of migraine in participants with episodic migraine. The study duration will be
approximately 6 months.